The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01X | Other antineoplastic agents | |
4
|
L01XX | Other antineoplastic agents | |
5
|
L01XX02 | Asparaginase |
| Active Ingredient |
|---|
|
Asparaginase hydrolyses asparagine to aspartic acid and ammonia. In contrast to normal cells, lymphoblastic tumour cells have a very limited capacity for synthesising asparagine because of a significantly reduced expression of asparagine synthetase. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells. |
| Document | Type | Information Source | |
|---|---|---|---|
| ENRYLAZE Solution for injection/infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| KIDROLASE Solution for injection | MPI, CA: SPM | Health Products and Food Branch (CA) | |
| RYLAZE Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.